WuXi Biologics (Cayman) Past Earnings Performance
Past criteria checks 3/6
WuXi Biologics (Cayman) has been growing earnings at an average annual rate of 41.4%, while the Life Sciences industry saw earnings growing at 22.4% annually. Revenues have been growing at an average rate of 40.8% per year. WuXi Biologics (Cayman)'s return on equity is 10.9%, and it has net margins of 25.1%.
Key information
41.4%
Earnings growth rate
39.1%
EPS growth rate
| Life Sciences Industry Growth | 12.9% |
| Revenue growth rate | 40.8% |
| Return on equity | 10.9% |
| Net Margin | 25.1% |
| Next Earnings Update | 26 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How WuXi Biologics (Cayman) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 16,554 | 4,152 | 1,956 | 753 |
| 31 Mar 23 | 15,911 | 4,286 | 1,824 | 718 |
| 31 Dec 22 | 15,269 | 4,420 | 1,693 | 683 |
| 30 Sep 22 | 14,179 | 4,251 | 1,472 | 670 |
| 30 Jun 22 | 13,090 | 4,081 | 1,251 | 657 |
| 31 Mar 22 | 11,690 | 3,735 | 1,192 | 579 |
| 31 Dec 21 | 10,290 | 3,388 | 1,133 | 502 |
| 30 Sep 21 | 9,183 | 3,092 | 1,043 | 398 |
| 30 Jun 21 | 8,075 | 2,795 | 952 | 295 |
| 31 Mar 21 | 6,844 | 2,242 | 837 | 299 |
| 31 Dec 20 | 5,612 | 1,689 | 722 | 304 |
| 30 Sep 20 | 4,967 | 1,494 | 648 | 289 |
| 30 Jun 20 | 4,321 | 1,300 | 574 | 275 |
| 31 Mar 20 | 4,152 | 1,157 | 512 | 267 |
| 31 Dec 19 | 3,984 | 1,014 | 451 | 260 |
| 30 Sep 19 | 3,535 | 922 | 427 | 241 |
| 30 Jun 19 | 3,087 | 831 | 404 | 222 |
| 31 Mar 19 | 2,811 | 731 | 365 | 196 |
| 31 Dec 18 | 2,534 | 631 | 326 | 169 |
| 30 Sep 18 | 2,277 | 520 | 270 | 132 |
| 30 Jun 18 | 2,019 | 410 | 214 | 94 |
| 31 Mar 18 | 1,819 | 331 | 195 | 84 |
| 31 Dec 17 | 1,619 | 253 | 175 | 74 |
| 30 Sep 17 | 1,429 | 177 | 155 | 66 |
| 30 Jun 17 | 1,233 | 149 | 128 | 60 |
| 31 Mar 17 | 1,111 | 145 | 119 | 56 |
| 31 Dec 16 | 989 | 141 | 110 | 53 |
| 30 Sep 16 | 889 | 171 | 101 | 61 |
| 31 Dec 15 | 557 | 45 | 86 | 40 |
| 31 Dec 14 | 332 | 42 | 48 | 35 |
Quality Earnings: 2269 N has high quality earnings.
Growing Profit Margin: 2269 N's current net profit margins (25.1%) are lower than last year (31.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2269 N's earnings have grown significantly by 41.4% per year over the past 5 years.
Accelerating Growth: 2269 N's earnings growth over the past year (1.7%) is below its 5-year average (41.4% per year).
Earnings vs Industry: 2269 N earnings growth over the past year (1.7%) exceeded the Life Sciences industry -1.9%.
Return on Equity
High ROE: 2269 N's Return on Equity (10.9%) is considered low.